Health Care [ 11/12 ] | Biotechnology [ 66/75 ]
NASDAQ | Common Stock
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer.
It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies.
Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -2.29 Decreased by -1.54 K% | -2.98 Increased by +23.15% |
| May 10, 24 | -3.74 Decreased by -750.00% | -2.23 Decreased by -67.71% |
| Mar 21, 24 | -1.99 Decreased by -729.17% | -2.84 Increased by +29.93% |
| Nov 13, 23 | -0.52 Decreased by -20.93% | -0.10 Decreased by -420.00% |
| Aug 14, 23 | -0.14 Increased by +69.57% | -0.16 Increased by +12.50% |
| May 11, 23 | -0.44 Decreased by -4.76% | -0.15 Decreased by -193.33% |
| Mar 31, 23 | -0.24 Increased by +44.19% | -0.41 Increased by +41.46% |
| Nov 14, 22 | -0.43 Decreased by -30.30% | -0.44 Increased by +2.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -14.92 M Increased by +20.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -24.30 M Increased by +56.85% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 7.67 M Increased by +N/A% | -12.93 M Increased by +76.00% | Decreased by -168.51% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -67.43 M Decreased by -19.93% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -18.66 M Increased by +68.37% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -56.33 M Decreased by -4.08% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -53.84 M Increased by +2.72% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -56.22 M Decreased by -30.74% | Decreased by N/A% Decreased by N/A% |